Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Certain genetic forms of dilated cardiomyopathy (DCM) entail a higher arrhythmic risk. It is unknown whether DCM patients with high-risk arrhythmic genotypes also develop more advanced heart failure (AHF) complications. AHF events were studied according to DCM genotype.
Methods: Clinical data from 1203 genotyped DCM patients were collected from 19 Spanish centres. Patients were classified into high-risk arrhythmic genotypes (LMNA, FLNC, desmosomal genes, PLN, TMEM43, RBM20), TTN, other genes, and genotype negative (Gen-). The primary endpoint was a composite of AHF events (ventricular assist device implantation, heart transplant, and AHF-related mortality). The secondary endpoint was a combination of malignant ventricular arrhythmias (MVA).
Results: A DCM-causing variant was identified in a high-risk arrhythmic gene in 185 patients (15.4%), 193 (16.0%) had variants in TTN, 134 (11.1%) in other genes, and 691 (57.4%) were Gen-. After a median follow-up of 5.7 years (interquartile range 2.9-9.1 years), AHF events occurred in 45 (24.3%) patients in the high-risk arrhythmic group, while in 25 (18.7%), 25 (13.0%), and 70 (10.1%) patients with other genotypes, TTN, and Gen-, respectively (hazard ratio 1.85, 95% confidence interval 1.31-2.61 for high-risk arrhythmic genes compared with other groups). MVA occurred in 55 patients (29.7%) (hazard ratio 2.52, 95% confidence interval 1.81-3.51 for high-risk genotypes vs other groups). High-risk arrhythmic genotype was the main independent predictor of AHF in multivariate analysis. High-risk arrhythmic genotype and late gadolinium enhancement were independent predictors of MVA.
Conclusions: Patients with high-risk arrhythmic genotypes also experience more AHF events, supporting a differential therapeutic approach in this group of patients beyond sudden death prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehaf605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure.
Eur Heart J
August 2025
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Manuel de Falla 1, Majadahonda, 28222 Madrid, Spain.
Background And Aims: Certain genetic forms of dilated cardiomyopathy (DCM) entail a higher arrhythmic risk. It is unknown whether DCM patients with high-risk arrhythmic genotypes also develop more advanced heart failure (AHF) complications. AHF events were studied according to DCM genotype.
View Article and Find Full Text PDFThe Clinical Significance of Atrial Fibrillation in Non-High-Risk Brugada Syndrome: The BruFib Study.
JACC Clin Electrophysiol
August 2025
Cardiology Department, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address:
Background: Atrial fibrillation (AF) occurs in up to 20% of patients with Brugada syndrome (BrS), yet its risk factors and prognostic implications remain uncertain.
Objectives: This study sought to identify risk factors for AF in patients with non-high-risk BrS and to evaluate the impact of AF on ventricular arrhythmias (VAs), sick sinus syndrome (SSS), and stroke in non-high-risk BrS.
Methods: This was a multicenter, retrospective study conducted across 20 international centers.
Assessing arrhythmic risk in chronic kidney disease: A study of the index of cardiac-electrophysiological balance.
J Res Med Sci
July 2025
Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Türkiye.
Background: Chronic kidney disease (CKD) patients are at high risk of cardiovascular death and malignant arrhythmia. We aimed to determine at which CKD stage, the change in the index of cardiac-electrophysiological balance (ICEB) value is more evident. Consequently, we included patients across all CKD stages in our research.
View Article and Find Full Text PDFThe role of adrenaline in comprehensive management of electrical storms in high-risk Brugada syndrome with rare SCN5A mutation: a case report from medical stabilization to implantable cardioverter-defibrillator implantation.
Eur Heart J Case Rep
August 2025
Pham Ngoc Thach University of Medicine, 2 Duong Quang Trung, 700000 Ho Chi Minh City, Vietnam.
Background: Patients with Brugada syndrome (BrS) have a risk of sudden cardiac death, often linked to mutations in the SCN5A gene. Electrical storms (ESs) in this population are life-threatening and typically require urgent administration of isoproterenol; however, in resource-limited settings, alternative pharmacologic strategies may be required. The management of ES in BrS is complex and often relies on case reports due to the rarity of the condition.
View Article and Find Full Text PDFStereotactic radiosurgery targeting the stellate ganglion for refractory ventricular arrhythmias: A first-in-human case report with 18-month follow-up.
Radiother Oncol
August 2025
Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Introduction: We present the first-in-human application of stereotactic radiosurgery (SRS) targeting the left stellate ganglion (LSG) as a non-invasive neuromodulatory strategy for treating polymorphic ventricular tachycardia/ventricular fibrillation (VT/VF).
Materials And Methods: A 69-year-old man with mixed-etiology cardiomyopathy (LVEF 28 %) experienced 27 VT/VF episodes over three months. This resulted in 18 implantable cardioverter-defibrillator (ICD) shocks and nine anti-tachycardia pacing therapies, despite optimal pharmacotherapy, catheter ablation and two temporary LSG blocks.